Results 351 to 360 of about 871,767 (407)
Some of the next articles are maybe not open access.
Tyrosine Kinase Inhibitors and Cancer Therapy
Clinical Biochemistry, 2004Cancer is the second leading cause of death in the western world. Despite advances in diagnosis and treatment, overall survival of patients remains poor. Scientific advances in recent years have enhanced our understanding of the biology of cancer. Human protein tyrosine kinases (PTKs) play a central role in human carcinogenesis and have emerged as the ...
Trivadi S. Ganesan +1 more
openaire +5 more sources
Receptor Tyrosine Kinase Inhibitors
2015Receptor tyrosine kinases (RTKs) are a diverse group of transmembrane proteins involved in signal transduction. Their function in many cell types is to drive a wide variety of cellular functions, including growth, differentiation and angiogenesis, by transducing growth factor signals from the external milieu to intracellular processes. In malignancies,
Antony M. Latham +2 more
openaire +3 more sources
Novel FLT3 tyrosine kinase inhibitors
Expert Opinion on Investigational Drugs, 2003Acute myeloid leukaemia (AML) is an aggressive haematological malignancy that is curable in approximately 40% of cases. Activating mutations of the receptor tyrosine kinase FLT3 (FMS-like tyrosine kinase-3) are the single most common molecular abnormalities in AML and are associated with a distinctly worse prognosis.
Donald Small, Mark J. Levis
openaire +3 more sources
Inhibitors of the insulin receptor tyrosine kinase
Pharmacology & Therapeutics, 1994Insulin is a polypeptide hormone consisting of 51 amino acids. Insulin promotes a variety of anabolic enzymatic pathways and inhibits many catabolic enzymatic pathways involved in energy storage, as well as in synthesis of structural tissue proteins.
Pothur R. Srinivas, George Grunberger
openaire +3 more sources
Tyrosine kinase inhibitors and the thyroid
Best Practice & Research Clinical Endocrinology & Metabolism, 2009Protein tyrosine kinase inhibitors (TKIs) have emerged as significant targets for novel cancer therapies. For patients with differentiated or medullary carcinomas unresponsive to conventional treatments, multiple novel therapies primarily targeting angiogenesis have entered clinical trials.
openaire +3 more sources
6 Protein Tyrosine Kinase Inhibitors
1996Publisher Summary This chapter describes the classification and structure of protein tyrosine kinases (PTKs), their mode of action, their cellular targets, and the processes in which they are involved. A vast amount of research has been carried out to try to identify the role of PTKs in the general functioning and development of normal mammalian ...
Kevin R. H. Solomons +3 more
openaire +3 more sources
Tyrosine Kinase Inhibitors in Pediatric Malignancies
Cancer Investigation, 2007Tyrosine kinase inhibitors have been used to treat adult cancers for over a decade. Since the discovery of imatinib mesylate (STI-571, Gleevec; Novartis), tyrosine kinase inhibitors have ushered in a new age of targeted therapy. Although the United States Food and Drug Administration has approved several kinase inhibitors for use in adult cancers ...
Peter C. Adamson, Jeffrey M. Skolnik
openaire +3 more sources
Tyrosine kinase inhibitor induced pancreatitis
Journal of Oncology Pharmacy Practice, 2012Sorafenib and sunitinib are oral tyrosine kinase inhibitors, commonly used in the treatment of metastatic renal cell carcinoma. Known adverse events associated with tyrosine kinase inhibitors include hypertension and palmarplantar erythrodysesthesia. We report two cases of acute pancreatitis associated with tyrosine kinase inhibitors.
Adrienne H. Chen +2 more
openaire +3 more sources
Tyrosine Kinase Inhibitors and Hepatocellular Carcinoma
Clinics in Liver Disease, 2020Sorafenib was the first tyrosine kinase inhibitor (TKI) that showed success in extending survival in patients with advanced hepatocellular carcinoma (HCC). In recent years, additional TKIs have been shown to improve survival and expanded the armamentarium for treating this malignancy.
Maria Reig +2 more
openaire +3 more sources
Tyrphostins and Other Tyrosine Kinase Inhibitors [PDF]
Annual Review of Biochemistry, 2006 The development of tyrosine phosphorylation inhibitors has transformed the approach to cancer therapy and is likely to affect other fields of medicine. In spite of the conservation among protein tyrosine kinases (PTKs), one can develop small molecules that block the activity of a narrow spectrum of PTKs and that exhibit much less toxicity than the ...
Eyal Mishani, Alexander Levitzki
openaire +2 more sources